Cargando…

MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1

Epithelial-mesenchymal transition (EMT) is one of important steps that lead to cancer metastasis. Interleukin-22 (IL-22) is a T helper 17 (Th17) cells-secreted cytokine, it can promote invasion and metastasis of many cancers. MiR-486-5p is a microRNA that known to function as a tumor suppressor, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongli, Mou, Qingjie, Li, Peirui, Yang, Zhiyi, Wang, Zhaoyan, Niu, Jie, Liu, Yuanyuan, Sun, Zhiliang, Lv, Shijun, Zhang, Baogang, Yin, Chonggao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746125/ https://www.ncbi.nlm.nih.gov/pubmed/31528235 http://dx.doi.org/10.7150/jca.30596

Ejemplares similares

Long non‐coding RNA ZEB2‐AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple‐negative breast cancer by epigenetically activating ZEB2
por: Zhang, Guoxin, et al.
Publicado: (2019)

Microarray expression profile of long non‐coding RNAs in human lung adenocarcinoma
por: Yang, Zhiyi, et al.
Publicado: (2018)

MiR‐577 suppresses epithelial‐mesenchymal transition and metastasis of breast cancer by targeting Rab25
por: Yin, Chonggao, et al.
Publicado: (2018)

MiR‐429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt/β‐catenin signaling pathway
por: Zhang, Liping, et al.
Publicado: (2020)

Linc00426 accelerates lung adenocarcinoma progression by regulating miR-455-5p as a molecular sponge
por: Li, Hongli, et al.
Publicado: (2020)

Vitamin D Inhibits IL-22 Production Through a Repressive Vitamin D Response Element in the il22 Promoter
por: Lopez, Daniel V., et al.
Publicado: (2021)

MIR22HG regulates miR-486/PTEN axis in bladder cancer to promote cell proliferation
por: Tang, Qisheng, et al.
Publicado: (2020)

LncRNA-AC009948.5 promotes invasion and metastasis of lung adenocarcinoma by binding to miR-186-5p
por: Bai, Jun, et al.
Publicado: (2022)

Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer
por: Shao, Yang, et al.
Publicado: (2016)

miR-486 Responds to Apoptosis and Autophagy by Repressing SRSF3 Expression in Ovarian Granulosa Cells of Dairy Goats
por: Liu, Shujuan, et al.
Publicado: (2023)

Building a Chinese pan-genome of 486 individuals
por: Li, Qiuhui, et al.
Publicado: (2021)

IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology
por: Zenewicz, Lauren A.
Publicado: (2021)

Cancer-associated fibroblast-derived exosomal miR-18b promotes breast cancer invasion and metastasis by regulating TCEAL7
por: Yan, Ziqian, et al.
Publicado: (2021)

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
por: Hanna, Jason A., et al.
Publicado: (2018)

miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer
por: Yu, Sunfeng, et al.
Publicado: (2018)

Targeting IL-22 and IL-22R protects against experimental osteoarthritis
por: Yi, Changhua, et al.
Publicado: (2020)

Downregulation of KIAA1199 by miR‐486‐5p suppresses tumorigenesis in lung cancer
por: Wang, Anqi, et al.
Publicado: (2020)

MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions
por: ElKhouly, Aisha M., et al.
Publicado: (2020)

RUNX represses Pmp22 to drive neurofibromagenesis
por: Hall, Ashley, et al.
Publicado: (2019)

PC 386/486 y pentium software estándar
por: Maass, K. 1961- (Klauss)
Publicado: (1994)

MicroRNA-486-5p Suppresses Lung Cancer via Downregulating mTOR Signaling In Vitro and In Vivo
por: Ding, Lei, et al.
Publicado: (2021)

MiR-507 inhibits the migration and invasion of human breastcancer cells through Flt-1 suppression
por: Jia, Liyan, et al.
Publicado: (2016)

miR-185-5p inhibits F-actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE
por: Yin, Chonggao, et al.
Publicado: (2018)

Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite)
por: Chen, Wenge, et al.
Publicado: (2017)

TME18/486: Multimedia Pattern Sets in Telemedicine Systems
por: Kacki, E, et al.
Publicado: (1999)

RU486 Mitigates Hippocampal Pathology Following Status Epilepticus
por: Wulsin, Aynara C., et al.
Publicado: (2016)

miR-486 is modulated by stretch and increases ventricular growth
por: Lange, Stephan, et al.
Publicado: (2019)

SUN-486 Unusual Presentation of Metastatic Follicular Thyroid Cancer
por: Proudan, Nikoletta, et al.
Publicado: (2020)

FRI486 Overactive Thyroid And Overactive Mind - An Intervened Relationship
por: Bilichodu Rangappa, Sushma, et al.
Publicado: (2023)

miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway
por: He, Ming, et al.
Publicado: (2017)

miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway
por: He, Ming, et al.
Publicado: (2023)

miR-486-5p and miR-22-3p Enable Megakaryocytic Differentiation of Hematopoietic Stem and Progenitor Cells without Thrombopoietin
por: Kao, Chen-Yuan, et al.
Publicado: (2022)

MiR-486 Regulates Lactation and Targets the PTEN Gene in Cow Mammary Glands
por: Li, Dan, et al.
Publicado: (2015)

Epidemiology and management of 10,486 pediatric fractures in Shenzhen: experience and lessons to be learnt
por: Qiu, Xin, et al.
Publicado: (2022)

Short- and long-term outcomes of 486 consecutive laparoscopic splenectomy in a single institution
por: Fu, Xiaowei, et al.
Publicado: (2021)

A Critical Role of the IL-22–IL-22 Binding Protein Axis in Hepatocellular Carcinoma
por: Giannou, Anastasios D., et al.
Publicado: (2022)

IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology
por: Wei, Hua-Xing, et al.
Publicado: (2020)

Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction
por: Zhang, Rui, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
por: Savona, Michael R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_71oucodhvpm2jb6d6r0h6rs0q4